

FDA-APPROVED BREAST CANCER TREATMENTS

Generic & Class	Brand & Company	Strength	Form	Usual Dose*
Alkylating Agents				
cyclophosphamide	Cytosan injection (Bristol Myers Squibb)	500mg, 1g, 2g	pwd for IV inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
	(various)	25mg, 50mg	tabs	1–5mg/kg/day
thiotepa	(various)	15mg, 30mg	pwd for IV, intravesical, or intracavitary administration after reconstitution	0.3–0.4mg/kg IV once every 1–4 weeks
Antibiotics (Cytotoxic)				
doxorubicin	Adriamycin (Bedford)	10mg, 20mg, 50mg	pwd for IV inj after reconstitution	Monotherapy: 60–75mg/m ² every 21 days Combination therapy: 40–60mg/m ² every 21 to 28 days
	Adriamycin Solution (Bedford)	2mg/mL	soln for IV inj	
epirubicin	Elice (Pfizer)	2mg/mL	soln for IV infusion	100–120mg/m ² on Day 1 or divided equally given on Days 1 and 8 of each cycle
Antiestrogen				
tamoxifen	(various)	10mg, 20mg	tabs	20–40mg/day
	Soltamox Oral Solution (DARA BioSciences)	10mg/5mL	oral soln	
toremifene	Fareston (GTX)	60mg	tabs	60mg once daily
Antimetabolites				
capecitabine	Xeloda (Genentech)	150mg, 500mg	tabs	Monotherapy: 1250mg/m ² twice daily Combination therapy: give with docetaxel 75mg/m ² IV infused over 1 hour every 3 weeks.
flourouracil	(various)	50mg/mL	soln for IV inj	12mg/kg once daily for 4 successive days; max 800mg/day
gemcitabine	Gemzar (Lilly)	200mg, 1g	pwd for IV infusion after reconstitution	1250mg/m ² on Days 1 and 8 of each 21 day cycle
methotrexate	Methotrexate injection (Bedford)	25mg/mL	soln for IV, IM, intra-arterial, or intrathecal administration after dilution	See drug entry and manufacturer's literature
		1g	pwd for IV, IM, intra-arterial, or intrathecal administration after dilution	
	Trexall (Teva)	5mg, 7.5mg, 10mg, 15mg	scored tabs	
Antimicrotubule agents				
docetaxel	Taxotere (Sanofi Aventis)	40mg/mL	soln for IV infusion after dilution	60–100mg/m ² once every 3 weeks
eribulin mesylate	Halaven (Eisai)	0.5mg/mL	soln for IV inj	1.4mg/m ² IV inj over 2–5min on Days 1 and 8 of each 21 day cycle.
ixabepilone	Ixempra (Bristol Myers Squibb)	15mg, 45mg	pwd for IV infusion after constitution and dilution	40mg/m ² once every 3 weeks
paclitaxel	Abraxane (Celgene) Taxol (Bristol Myers Squibb)	100mg	IV infusion; inj susp after reconstitution	260mg/m ² every 3 weeks
		6mg/mL	soln for IV infusion after dilution	175mg/m ² every 3 weeks
vinblastine for injection	(Bedford)	10mg	lyophilized pwd for IV inj or infusion after reconstitution	5.5–7.4mg/m ² once weekly (see literature)
vinblastine injection	(Abraxis Oncology)	1mg/mL	soln for IV inj or infusion	
Aromatase Inhibitor				
anastrozole	Arimidex (AstraZeneca)	1mg	tabs	1mg once daily
exemestane	Aromasin (Pfizer)	25mg	tabs	25mg once daily
letrozole	Femara (Novartis)	2.5mg	tabs	2.5mg once daily
Estrogen				
estradiol	Estrace (Warner Chilcott)	0.5mg, 1mg, 2mg	scored tabs	10mg 3 times daily for at least 3 months
Estrogen Receptor Antagonist				
fulvestrant	Faslodex (AstraZeneca)	50mg/mL	soln for IM inj	500mg on days 1, 15, 29, then once per month thereafter
GnRH Analogue				
goserelin	Zoladex (AstraZeneca)	3.6mg	SC implant	One 3.6mg implant every 28 days
Human Epidermal Growth Factor Receptor (HER2) Inhibitor				
pertuzumab	Perjeta (Genentech)	420mg/14mL (30mg/mL)	soln for IV infusion	Initially 840mg IV over 60 minutes, followed every 3 weeks thereafter by a dose of 420mg IV over 30–60 minutes in combination with trastuzumab and docetaxel. Dose modification (missed dose, LVEF, or infusion reactions): see literature.
		trastuzumab	Herceptin (Genentech)	
mTOR Kinase Inhibitor				
everolimus	Afinitor (Novartis)	2.5mg, 5mg, 7.5mg, 10mg	tabs	10mg once daily
Progestin				
megestrol acetate	Megace (Bristol Myers Squibb)	20mg, 40mg	scored tabs	40mg 4 times daily
Selective Estrogen Receptor Modulator (SERM)				
raloxifene	Evista (Lilly)	60mg	tabs	60mg once daily
Tyrosine Kinase Inhibitor				
lapatinib	Tykerb (GlaxoSmithKline)	250mg	tabs	See drug entry and manufacturer's literature

* For more detailed dosing information, see drug entry.

(Rev. 11/2012)